Cargando…

Adnexal mass with extremely high levels of CA-125 and CA19-9 but normal Human Epididymis Protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA): Endometriosis or ovarian malignancy? A case report

BACKGROUND: It has been shown that Carbohydrate antigen (CA) 125 and CA 19-9 tumor markers are useful for diagnosis and follow up of ovarian carcinoma. CASE: In this case, we reported the high level of CA-125 and CA 19-9 with large right ovarian intact endometrioma and extensive involvement of oment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khodaverdi, Sepideh, Amini-Moghaddam, Soheila, Almassi Nokiani, Fariba, Hashemi, Neda, Mohammad Beigi, Robabeh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Research and Clinical Center for Infertility 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079310/ https://www.ncbi.nlm.nih.gov/pubmed/30123870

Ejemplares similares

Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses
por: Terlikowska, Katarzyna M., et al.
Publicado: (2016)

A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses
por: Anton, Cristina, et al.
Publicado: (2012)

Are ROMA and HE4 More Accurate than CA-125, in Predicting of Ovarian Epithelial Carcinoma?
por: Behnamfar, Fariba, et al.
Publicado: (2023)

Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors
por: Carreras-Dieguez, Núria, et al.
Publicado: (2022)

The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer
por: WEI, SU, et al.
Publicado: (2016)

Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women
por: Fujiwara, Hiroyuki, et al.
Publicado: (2014)

Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses
por: Dewan, Rupali, et al.
Publicado: (2019)

Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis
por: Shin, Kyung-Hwa, et al.
Publicado: (2020)

Performance of IOTA Simple Rules Risks, ADNEX Model, Subjective Assessment Compared to CA125 and HE4 with ROMA Algorithm in Discriminating between Benign, Borderline and Stage I Malignant Adnexal Lesions
por: Czekierdowski, Artur, et al.
Publicado: (2023)

Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: A meta-analysis
por: Li, Fake, et al.
Publicado: (2012)

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses
por: Pitta, Denise da Rocha, et al.
Publicado: (2013)

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
por: Dochez, Vincent, et al.
Publicado: (2019)

Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria
por: Shittu, Khadijah Adebisi, et al.
Publicado: (2023)

Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women
por: Cho, Hye Yon, et al.
Publicado: (2015)

Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?
por: Abdalla, Nabil, et al.
Publicado: (2018)

Comparison of Ultrasound and Tumor Marker CA125 in Diagnosis of Adnexal Mass Malignancies
por: Behnamfar, Fariba, et al.
Publicado: (2022)

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
por: Van Gorp, T, et al.
Publicado: (2011)

Copenhagen index (CPH-I) is more favorable than CA125, HE4, and risk of ovarian malignancy algorithm (ROMA): Nomogram prediction models with clinical-ultrasonographic feature for diagnosing ovarian neoplasms
por: Song, Zixuan, et al.
Publicado: (2023)

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases
por: Molina, Rafael, et al.
Publicado: (2011)

Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam
por: Huy, Nguyen Vu Quoc, et al.
Publicado: (2018)

Assessment of Diagnostic Values among CA-125, RMI, HE4, and ROMA for Cancer Prediction in Women with Nonfunctional Ovarian Cysts
por: Oranratanaphan, Shina, et al.
Publicado: (2018)

Diagnostic Performance of F-18 FDG PET/CT Compared with CA125, HE4, and ROMA for Epithelial Ovarian Cancer
por: Lee, Sun Seong, et al.
Publicado: (2021)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4
por: Han, Kyung Hee, et al.
Publicado: (2019)

Can Replacing CA125 with HE4 in Risk of Malignancy Indices 1–4 Improve Diagnostic Performance in the Presurgical Assessment of Adnexal Tumors?
por: Abdalla, Nabil, et al.
Publicado: (2017)

Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer
por: Zhang, Pengjun, et al.
Publicado: (2015)

Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial
por: Dochez, Vincent, et al.
Publicado: (2019)

The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer
por: Anastasi, Emanuela, et al.
Publicado: (2013)

The added value of CA125, HE4, and CA72-4 as markers for ovarian endometriosis diagnosis
por: Micu, Romeo, et al.
Publicado: (2023)

Multivariate Index Assay Is Superior to CA125 and HE4 Testing in Detection of Ovarian Malignancy in African-American Women
por: Dunton, Charles, et al.
Publicado: (2019)

Preoperative Evaluation of Risk of Ovarian Malignancy Algorithm Index in Prediction of Malignancy of Adnexal Masses
por: Farzaneh, Farah, et al.
Publicado: (2014)

The Use of Human Epididymis 4 and Cancer Antigen 125 Tumor Markers in the Benign or Malignant Differential Diagnosis of Pelvic or Adnexal Masses
por: Dolgun, Zehra Nihal, et al.
Publicado: (2017)

Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125
por: Chudecka-Głaz, Anita, et al.
Publicado: (2016)

Diagnostic value of the gynecology imaging reporting and data system (GI-RADS) with the ovarian malignancy marker CA-125 in preoperative adnexal tumor assessment
por: Migda, Michal, et al.
Publicado: (2018)

The International Ovarian Tumor Analysis-Assessment of Different Neoplasias in the Adnexa (IOTA-ADNEX) Model Assessment for Risk of Ovarian Malignancy in Adnexal Masses
por: Cherukuri, Srinidhi, et al.
Publicado: (2022)

Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses
por: Gentry-Maharaj, Aleksandra, et al.
Publicado: (2020)

Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer
por: Zhu, Liancheng, et al.
Publicado: (2015)

Predicting Malignancy in Adnexal Masses by the International Ovarian Tumor Analysis-Simple Rules
por: Solanki, Vrushti, et al.
Publicado: (2020)

Evaluation of the Diagnostic Value of the Ultrasound ADNEX Model for Benign and Malignant Ovarian Tumors
por: Peng, Xiao-Shan, et al.
Publicado: (2021)

Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women
por: Barr, Chloe E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g6vm74gg0fgae9vngb86nen3l1